The Journal of Pediatrics
Volume 155, Issue 4, Supplement , Pages S32-S46 , October 2009

Guidelines for the Management of Mucopolysaccharidosis Type I

  • Ana Maria Martins, MD, PhD

      Affiliations

    • Centro de Referência em Erros Inatos do Metabolismo, Universidade Federal de São Paulo, São Paulo, Brazil
    • Corresponding Author InformationReprint requests: Ana Maria Martins, Rua Joaquim Antunes, 620/72 CEP 05415-010–São Paulo, SP, Brazil.
    • ,
  • Ana Paula Dualibi, MD, PhD

      Affiliations

    • Disciplina de Otorrinolaringologia Pediátrica da Universidade Federal de São Paulo, São Paulo, Brazil
    • ,
  • Denise Norato, MD, PhD

      Affiliations

    • Pontifícia Universidade Católica de Campinas, São Paulo, Brazil
    • ,
  • Edna Tiemi Takata, MD

      Affiliations

    • Centro de Referência em Erros Inatos do Metabolismo, Universidade Federal de São Paulo, São Paulo, Brazil
    • ,
  • Emerson S. Santos, MD

      Affiliations

    • Universidade de Ciências da Saúde de Alagoas, Maceio, Brazil
    • ,
  • Eugênia Ribeiro Valadares, MD, PhD

      Affiliations

    • Departamento de Propedêutica Complementar da Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
    • ,
  • Gilda Porta, MD, PhD

      Affiliations

    • Departamento de Pediatria, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
    • ,
  • Gisele de Luca, MD

      Affiliations

    • Universidade Estácio de Sá, Florianópolis, Disciplina Medicina e Biologia do Sono, Departamento de Psicobiologia, São Paulo, Brazil
    • ,
  • Gustavo Moreira, MD, PhD

      Affiliations

    • Universidade Federal de São Paulo, São Paulo, Brazil
    • ,
  • Helena Pimentel, MD

      Affiliations

    • Triagem Neonatal, Associação de Pais e Amigos do Excepcionais/APAE, Salvador, Bahia, Brazil
    • ,
  • Janice Coelho, PhD

      Affiliations

    • Departamento de Bioquímica-ICBS, Universidade Federal do Rio Grande do Sul e Serviço de Genética Médica do Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
    • ,
  • Jaime Moritz Brum, MD, PhD

      Affiliations

    • Medicina Laboratorial da Rede Sarah de Hospitais de Reabilitação, Belo Horizonte, Brazil
    • ,
  • José Semionato Filho, MD

      Affiliations

    • Centro Geral de Pediatria, Fundação Hospitalar do Estado de Minas Gerais, Belo Horizonte, Brazil
    • ,
  • Marcelo Soares Kerstenetzky, MD

      Affiliations

    • Serviço de Hepatologia Infantil do Hospital da Restauração – Pernambuco, Recife, Brazil
    • ,
  • Márcia R. Guimarães, MD

      Affiliations

    • Departamento de Oftalmologia da Faculdade de Medicine de Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
    • ,
  • Maria Verónica Muñoz Rojas, MD

      Affiliations

    • Setor de Mucopolissacaridose do Serviço de Genética Médica do Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
    • ,
  • Paulo Cesar Aranda, MD

      Affiliations

    • Serviço de Hematologia do Hospital Evangélico de Londrina – Paraná, Londrina, Brazil
    • ,
  • Ricardo Flores Pires, MD

      Affiliations

    • Clínica de Doenças Metabólicas Dr Ricardo Pires, Porto Alegre, Brazil
    • ,
  • Rodrigo G.C. Faria, MD

      Affiliations

    • Serviço de Ortopedia Pediátrica do Hospital Socor, Belo Horizonte, Brazil
    • ,
  • Ronald Moura Vale Mota, MD

      Affiliations

    • Serviço de Ortopedia Pediátrica do Hospital Socor, Belo Horizonte, Brazil
    • ,
  • Ursula Matte, PhD

      Affiliations

    • Laboratório de Terapia Gênica, Centro de Pesquisas do Hospital de Clínicas de Porto Alegre/Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
    • ,
  • Zelita Caldeira Ferreira Guedes, PhD

      Affiliations

    • Disciplina de Distúrbios da Comunicação Humana, Departamento de Fonoaudiologia da Universidade Federal de São Paulo, São Paulo, Brazil

References 

  1. Meikle P, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysossomal storage disorders. JAMA. 1999;281:249–254
  2. Lowry RB, et al. An update on the frequency of mucopolysaccharide syndromes in British Columbia. Hum Genet. 1990;86:389–390
  3. Poorthuis BJHM, et al. The frequency of lysosomal storage disease in the Netherlands. Hum Genet. 1999;105:151–156
  4. Moore D, Connock MJ, Wraith E, Lavery C. The prevalence of and survival in mucopolysaccharidosis I: Hurler, Hurler-Scheie, and Scheie syndromes in the UK. Orphanet J Rare Dis. 2008;3:24;[Epub ahead of print]
  5. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In:  Scriver C,  Beaudet A,  Sly W, et al. editor. The metabolic and molecular bases of inherited disease. New York: McGraw Hill; 2001;p. 3421–3452
  6. Online Mendelian Inheritance in Man, OMIM. Johns Hopkins University, Baltimore, MD. MIM Number: 607014, last edited: 10/6/2003. Available at: http://www.ncbi.nlm.nih.gov/omim.
  7. Wraith JE. The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Child. 1995;72:263–267
  8. Martins AM, et al. Mucopolissacaridoses: Manual de Orientações. Avaliable at: http://www.unifesp.br/centros/creim/downloads/gz-mps-apostila-2003.pdf.
  9. Wraith JE. MPS I management and treatment guidelines. Am J Hum Genet. 2003;73:621
  10. Shapiro J, Strome M, Croker AC. Airway obstruction and sleep apnea in Hurler and Hunter syndromes. Ann Otol Rhinol Laryngol. 1985;94:458–461
  11. Carroll JL, Loughlin GM. Obstructive sleep apnea syndrome in infants and children: diagnosis and management. In:  Ferber R,  Kryger M editor. Principles and practice of sleep medicine in the child. Philadelphia: W.B. Saunders Company; 1995;p. 193–216
  12. Moreira GA., Pradella-Hallinan MC., Rueda AD, Barbisan BN, Tufik S. Nasal positive pressure for children with sleep disordered breathing. In: Latin American Sleep Congress, 8, Sao Paulo, 2000. Abstracts. Hypnos 2000;1:73.
  13. Chan D, Li AM, Yam MC, Li CK, Fok TF. Hurler's syndrome with cor pulmonale secondary to obstructive sleep apnoea treated by continuous positive airway pressure. J Pediatric Child Health. 2003;39:558–559
  14. American Thoracic Society . Indications and standards for cardiopulmonary sleep studies. Am Rev Respir Dis. 1989;139:559–568
  15. American Thoracic Society . Cardiorespiratory sleep studies in children. Establishment of normative data and polysomnographic predictors of morbidity. Am J Respir Crit Care Med. 1999;160:1381–1387
  16. Marcus CL. Sleep-disordered breathing in children. Am J Respir Crit Care Med. 2001;164:16–30
  17. Mcnamara F, Sullivan CE. Obstructive sleep apnea in infants and its management with nasal continuous positive airway pressure. Chest. 1999;116:10–16
  18. Moreira GA, Pradella-Hallinan MC, Barbisan BN, Tufik S. Sleep disorders in children with mucopolysaccharidosis. In: Associated Professionals Sleep Society Annual Meeting, 15, Chicago, June 17-22, 2001. Abstracts. Sleep, 2001;24(abstract suppl):A210.
  19. Guilleminault C, Pelayo R, Leger D, Clerk A, Bocian RC. Recognition of sleep-disordered breathing in children. Pediatrics. 1996;98:871–882
  20. Myer CM. Airway obstruction in Hurler's syndrome: radiographic features. Int J Pediatr Otorhinolsryngol. 1991;22:91–96
  21. Casselbrant ML. Methods of examination. In:  Bluestone CD,  Stool SE,  Kenna MA editor. Pediatric otolaryngology. 3rd ed. Philadelphia: W B Saunders Co; 1996;
  22. Semenza GL, Pyeritz RE. Respiratory complications of mucopolysaccharide storage disorders. Medicine. 1988;67:209–219
  23. Bredenkamp JK, Smith ME, Dudley JP, Williams JC, Crumley RL, Crockett DM. Otolayngologic manifestations of the mucopolysaccharidoses. Ann Otol Rhinol Layngol. 1992;101:472–478
  24. Mac Arthur, Glicklich R, McGill TJI, Perez-Atayde A. Sinus complications in mucopolysaccharidoses I H/S (Hurler-Scheie syndrome). Int J Pediatr Otorhinolsryngol. 1993;26:79–87
  25. Wald ER. Rhinitis and acute and chronic sinusitis. In:  Bluestone CD,  Stool SE,  Kenna MA editor. Pediatric otolaryngology. 3rd ed. Philadelphia: W B Saunders Co; 1996;
  26. Nayak DR, Balakrishnan R, Adolph S. Endoscopic adenoidectomy in a case of Scheie syndrome. Int J Pediatr Otorhinolaryngol. 1998;44:177–181
  27. Wetmore R. Tracheotomy. In:  Bluestone CD,  Stool SE,  Kenna MA editor. Pediatric otolaryngology. 3rd ed. Philadelphia: W B Saunders Co; 1996;
  28. Maddern BR. Obstructive sleep disorders. In:  Bluestone CD,  Stool SE,  Kenna MA editor. Pediatric otolaryngology. 3rd ed. Philadelphia: W B Saunders Co; 1996;
  29. Allen JL. Treatment of respiratory system (not just lung!) abnormalities in mucopolysaccharidosis I. J Pediatr. 2004;144:581–588
  30. Shinhar SY, Zablocki H, Madgy DN. Airway management in mucopolysaccharide storage disorders. Arch Otolaryngol Head Neck Surg. 2004;130:233–237
  31. Ard JL, Bekker A, Frempong-Boadu AK. Anesthesia for an adult with mucopolysaccharidosis I. J Clin Anesth. 2005;17:624–626
  32. Walker RWM, Colovic V, Robinson DN, Dearlove OR. Postobstrutive pulmonary oedema during anaesthesia in children with mucopolysaccharidoses. Paed Anaesth. 2003;13C:441–447
  33. Ruckenstein MJ, MacDonald RE, Clarke JTR, Forte V. The management of otolaryngological problems in the mucopolysaccharidoses: a retrospective review. J Otolaryngol. 1991;20:177–183
  34. Motamed M, Thorne S, Narula A. Treatment of otitis media with effusion in children with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol. 2000;53:121–124
  35. Hayes E, Babin R, Platz C. The otologic manifestatiosn of mucopolysaccharidoses. Am J Otol. 1980;2:65–69
  36. Friedmann I, Spellacy E, Crow J, Watts RWE. Histopathological studies of the temporal bones in Hurler's disease. J Laryngol Otol. 1985;99:29–41
  37. Schachern PA, Shea DA, Papparella MM. Mucopolysaccharidoses IH (Hurler's syndrome) and human temporal bone histopatholoy. Ann Otol Rhinol Laryngol. 1984;93:65–69
  38. Oghan F, Harputluoglu U, Guclu E, Guvey A, Turan N, Ozturk O. Permanent t-tube insertion in two patients with Hurler's syndrome. Int J Audiol. 2007;46:94–96
  39. Wraith JE, Cleary MA. The presenting features of mucopolysaccharidosis type IH (Hurler syndrome). Acta Pediatr. 1995;
  40. Martins M, Fonseca MH. Repercussões psico-sociais na criança com Mucopolissacaridose. Acta Medica Portuguesa. 1995;5:329–334
  41. Becker E. Deficiências: alternativas de intervenção. Casa do Psicólogo. 1997;95:31–52
  42. Seto T, et al. Brain magnetic resonance imaging in 23 patients with mucopolysaccharidoses and the effect of bone marrow transplantation. Ann Neurol. 2001;50:79–92
  43. Watts RWE, Spellacy E, Kendall BE, du Boulay G, Gibbs DA. Computed tomography studies on patients with mucopolysaccharidoses. Neuroradiology. 1981;21:9–23
  44. Sheridan M, Johnston . Hydrocephalus and pseudomotor cerebri in the mucopolysaccharidoses. Childs Nerv Syst. 1994;10:148–150
  45. Barone R, Parano E, Trifiletti RR, Fiumara A, Pavone P. White matter changes mimicking a leukodystrophy in a patient with mucopolysaccharidosis: characterization by MRI. J Neurolog Sci. 2002;195:171–175
  46. Herman MJ, Pizzutillo PD. Cervical spine disorders in children. Orthoped Clin North Am. 1999;30:457–466
  47. Taccone A, Donati PT, Marzoli A, Acqua AD, Gatti R, Leone D. Mucopolysaccharidosis: thickening of dura mater at the craniocervical junction and other CT/MRI findings. Pediatr Radiol. 1993;23:349–352
  48. Kachur E, Maestro RD. Mucopolysaccharidoses and spinal cord compression: case report and review of the literature with implications of bone marrow transplantation. Neurosurgery. 2000;47:223–229
  49. Dalvie SS, Noorden FRCS, Vellodi A. Anterior instrumented fusion for thoracolumbar kyphosis in mucopolysaccharidosis. Spine. 2001;(26):E539–E541
  50. Pierpont MEM, Moller JH. Cardiac manifestations of genetic disease. In:  Moss Adams editors. Heart disease in infants, children, and adolescents. 5th ed. London: Williams & Wilkins; 1995;p. 1486–1520
  51. Soliman OII, Timmermans RGM, Nemes A, et al. Cardiac abnormalities in adults with the attenuated form of mucopolysaccharidosis type I. J Inherit Metab Dis. 2007;Published online
  52. Donaldson MDC, Pennock CA, Berry PJ, et al. Hurler syndrome with cardiomyiopathy in infancy. J Pediatr. 1989;114:430–432
  53. Farina V, Leva F, Caso P, et al. Echo-Doppler abnormalities in mucopolysaccharide storage diseases. Acta Paediatr. 1992;81:702–704
  54. Mohan UR, Hay AA, Cleary MA, et al. Cardiovascular changes in children with mucopysaccharide disorders. Acta Paediatr. 2002;91:799–804
  55. Dangel JH. Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders—clinical and echocardiographic findings in 64 patients. Eur J Pediatr. 1998;157:534–538
  56. Rigante D, Segni G. Cardiac structural involviment in mucopolysaccharidoses. Cardiology. 2002;98:18–20
  57. Fischer TA, Lehr HA, Nixdorff U, Meyer J. Combined aortic and mitral stenosis in mucopolysaccharidosis type I-S (Ullrich-Scheie syndrome). Heart. 1999;81:97–99
  58. Minakata K, Konishi Y, Matsumoto M, Miwa S. Surgical treatment for Scheie syndrome (mucopolysaccharidosis type I-S)—report of two cases. Jpn Circ J. 1998;62:700–703
  59. Belmont PJ. Early diagnosis of Hurler's syndrome with the aid of the identification of the characteristic gibbus deformity. Mil Med. 1998;10:711–714
  60. Matsui Y, Kawabata H, Nakayama M, Ozono , Keiichi , Kitoch H, et al. Sheie syndrome (MPS-IS) presented as bilateral trigger thumb. Pediatr Int. 2003;
  61. Grossman H. Progress in pediatric radiology, intrinsic desease of bones. In: Kaufmann HJ, editor. Philadelphia:1973. p. 495–544.
  62. Taybi H, Lachman RS. Radiology of syndromes, metabolic disorders, and skeletal dysplasias. Mosby; 1996;p. 670-81
  63. Khanna G, Van Heest AE, Agel J, Bjoraker K, Grewal S, Abel S, et al. Analysis of factors affecting development of carpal tunnel syndrome in patients with Hurler syndrome after hematopoietic cell transplantation. Bone Marrow Transplant. 2007;39:331–334
  64. Haddad FS, Jones DHA, Vellodi A, et al. Carpal tunel syndrome in the mucopolysaccharidoses. J Bone Joint Surg. 1997;(79-B):576–582
  65. Sillence D. Neurological complications of MPS. In: 4th International Symposium on Mucopolysaccharide and Related Diseases program. Wollongong, Australia. 1996;p. 36
  66. Masterson EL, Murphy PG, O'Meara A, Moore DP, Dowling FE, Fogarty EE. Hid dysplasia in Hurler's syndrome: orthopaedic management after bone marrow transplantation. J Paediatr Orthopaed. 1996;16:731–733
  67. Wraith JE, Alani SM. Carpal tunnel syndrome in the mucopolysaccharidosis and related disorders. Arch Dis Child. 1990;65:962–963
  68. Pronicka E, Tylki-Szymanska A, Kwast O, Chmielik J, Maciejko D, Cedro A. Carpal tunnel syndrome in children with mucopolysaccharidoses: needs for surgical tendons and median nerve release. J Ment Defic Res. 1988;32(Pt 1):79–82
  69. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme replacement therapy in, ucopolysaccharidosis I. N Engl J Med. 2001;344:182–188
  70. Wraith JE, Beck M, Lane R, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha- L-iduronidase (laronidase). Pediatrics. 2007;120:e37–e46
  71. Grupcheva CN, Craig J, McGhee NJ. In vivo microstructural analysis of the cornea in Schei's syndrome. Cornea. 2003;22:76–79
  72. Ashworth JL, Biswas S, Wraith E, Lloyd C. The ocular features of the mucopolysaccharidoses. Eye. 2005;20:553
  73. Ashworth JL, Biswas S, Wraith E, Lloyd C. Mucoppolysaccharidoses and the eye. Surv Ophthalmol. 2006;51:1–17
  74. Scott HS, Ashton LJ, Eyre HJ, Baker E, Brooks DA, Callen DF, et al. Chromosomal localization of the human alpha-L-iduronidase gene (IDUA) to 4p16.3. Am J Hum Genet. 1990;47:802–807
  75. Scott HS, Litjens T, Hopwood JJ, Morris CP. A common mutation for mucopolysaccharidosis type I associated with a severe Hurler phenotype. Hum Mutat. 1992;1:103–108
  76. Scott HS, Guo XH, Hopwood JJ, Morris CP. Structure and sequence of the human alpha-L-iduronidase gene. Genomics. 1992;13:1311–1313
  77. Scott HS, et al. Alpha-L-iduronidase mutations (Q70X and P533R) associated with a severe Hurler phenotype. Hum Mutat. 1992;1:333–339
  78. Bunge S, Kleijer WJ, Steglich C, Beck M, Zuther C, Morris CP, et al. Mucopolysaccharidosis type I: identification of 8 novel mutations and determination of the frequency of the two commom alpha-L-iduronidase mutations (W402X and Q70X) among European patients. Hum Mol Genet. 1994;3:861
  79. Gort L, Chabs Coll MJ. Analysis of five mutations in 20 mucopolysaccharidosis type I patients: high prevalence of the W402X mutation. Hum Mutat. 1998;11:332
  80. Voskoboeva EY, Krasnopolskaya XD, Mirenburg TV, Weber B, Hopwood JJ. Molecular genetics of mucopolysaccharidosis type I: mutation analysis among the patients of the former Soviet Union. Mol Genet Metab. 1998;65:174
  81. Bach G, Moskowitz SM, Tieu PT, Matynia A, Neufeld EF. Molecular analysis of Hurler syndrome in Druze and Muslim patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area. Am J Hum Genet. 1993;53:330
  82. Yamagishi A, Tomatsu S, Fukuda S, Uchiyama A, Shimozawa N, Susuki Y, et al. Mucopolysaccharidosis type I patients: identification of common mutations that cause Hurler and Scheie syndromes in Japanese populations. Hum Mutat. 1996;7:23
  83. Matte U, Yogalingam G, Brooks D, Leistner S, Schwatz I, Lima L, et al. Identification and characterization of 13 new mutations in mucopolysaccharidosis type I patients. Mol Genet Metab. 2003;78:37–43
  84. Aronovich EL, Pan D, Whiteley CB. Molecular genetic defect underlying alpha-L-iduronidase pseudodeficiency. Am J Hum Genet. 1996;58:75–85
  85. Chamoles NA, Blanco M, Gaggioli D. Diagnosis of alpha-L-iduronidase deficiency in dried blood spots on filter paper: the possibility 0f newborn diagnosis. Clin Chem. 2001;47:780–781
  86. Chamoles NA, Blanco M, Gaggioli D, Casentini C. Hurler-like phenotype: enzuimatic diagnosis in dried blood spots on filter paper. Clin Chem. 2001;47:2098–2102
  87. Pastores GM, Arn P, Beck M, Clarke JT, Guffon N, Kaplan P, et al. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with mucopolysaccharidosis type I. Mol Genet Metab. 2007;91:37–47
  88. Hingston EJ, Hunter ML, Hunter B, Drage N. Hurler's syndrome: dental findings in a case treated with bone marrow transplantation in infancy. Int J Paediatr Dent. 2006;16:207–212
  89. Guven G, Cehreli ZC, Altun C, Sencimen M, Ide S, Bayari SH, et al. Mucopolysaccharidosis type I (Hurler syndrome): oral and radiographic findings and ultrastructural/chemical features of enamel and dentin. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Jun 27, 2007;[Epub ahead of print]
  90. Dusing SC, Thorpe D, Rosenberg A, Mercer V, Escolar ML. Gross motor abilities in children with Hurler syndrome. Dev Med Child Neurol. 2006;48:927–930
  91. Haley SM, Fragala , Pinkham MA, Dumas HM, Ni P, Skrinar AM, et al. A physical performance measure for individuals with mucopolysaccharidosis type I. Dev Med Child Neurol. 2006;48:576–581
  92. Evangelista LMC. As novas abordagens do diagnóstico psicológico da deficiência mental. 1st ed. São Paulo: Vetor; 2002;p. 33-76, 217-50
  93. Skinner-Thompson. Exercícios na água. São Paulo: Editora: Manole; 1985.
  94. Kelly M, Darrah J. Aquatic exercise for children with cerebral palsy. Dev Med Child Neurol. 2005;47:838–842
  95. Norm A, Hanson B. Exercícios aquáticos terapêuticos. São Paulo: Manole. 1998;
  96. Ruoti RG, Morris DM, Cole AJ. Efeitos fisiológicos da imersão em repouso. In:  Bookspan J editors. Reabilitação aquatica. São Paulo: Manole; 2000;p. 29–42
  97. Schiffmann R, Brady RO. New prospects for the treatment of lysosomal storage diseases. Drugs. 2002;62:733–742
  98. Staba SL, Escolar ML, Poe M, Kim Y, Martin PL, Szabolcs P, et al. Cord-bood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med. 2004;350:1960–1969
  99. Peters C, Steward CG. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant. 2003;31:229–239
  100. Fujisaki G, Kami M, Kishi Y. Cord-blood transplants from unrelated donors in Hurler's syndrome. N Engl J Med. 2004;350:1960–1969
  101. Baxter MA, Wynn RF, Schyma L, Holmes DK, Wraith JE, Fairbairn LJ, et al. Marrow stromal cells from patients affected by MPS I differentially support haematopoietic progenitor cell development. J Inherit Metab Dis. 2005;28:1045–1053
  102. Church H, Tylee K, Cooper A, Thornley M, Mercer J, Wraith E, et al. Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease. Bone Marrow Transplant. 2007;39:207–210
  103. Braunlin EA, Rose AG, Hopwood JJ, Candel RD, Krivit W. Coronary artery patency following long-term successful engraftment 14 years after bone marrow transplantation in the Hurler syndrome. Am J Cardiol. 2001;88:1075–1077
  104. Souillet G, Guffon N, Maire I, Pujol M, Taylor P, Sevin F, et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant. 2003;31:1105–1117
  105. Braunlin EA, Stauffer NR, Peters CH, Bass JL, Berry JM, Hopwood JJ. Usefulness of bone marrow transplantation in the Hurler syndrome. Am J Cardiol. 2003;92:882–886
  106. Taylor C, Brady P, O'Meara A, Moore D, Dowling F, Fogarty E. Mobility in Hurler syndrome. J Pediatr Orthop. 2008;28:163–168
  107. Hugh-Jones K. Psychomotor development of children with mucopolysaccharidoses type 1-H following bone marrow transplantation. Birth Defects. 1986;22:25
  108. Peters C, Balthazor M, Shapiro EG, King RJ, Kollman C, Hegland JD, et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood. 1996;87:4894–4902
  109. Vellodi A, Young EP, Cooper A, Wraith JE, Winchester B, Meaney C, et al. Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centers. Arch Dis Child. 1997;76:92–99
  110. Soni S. Allogeneic stem cell transplantation for genetic disorders. J Ky Med Assoc. 2007;105:12–16
  111. Fleming DR, Henslee-Downey PJ, Ciocci G, Romond EH, Marciniak E, Munn RK, et al. The use of partially HLA-mismatched donors for allogenic transplantation in patients with mucopolysacharidosis-I. Pediatr Transplant. 1998;2:299–304
  112. Grewal SS, Krivit W, Defor TE, Shapiro EG, Orchard PJ, Abel SL, et al. Outcome of second hematopoietic cell transplantation in Hurler syndrome. Bone Marrow Transplant. 2002;29:491–496
  113. Peters C, Shapiro EG, Anderson J, Henslee-Downey PJ, Klemperer MR, Cowan MJ, et al. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. Blood. 1998;91:2601–2608
  114. Lange MC, Teive HA, Troiano AR, Bitencourt M, Funke VA, Setúbal DC, et al. Bone marrow transplantation in patients with storage diseases: a developing country experience. Arq Neuropsiquiatr. 2006;64:1–4
  115. Boelens JJ, Wynn RF, O'Meara A, et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007;40:225–233
  116. Grewal SS, Wynn R, Abdenur JE, Burton BK, Gharib M, Haase C, et al. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med. 2005;7:143–146
  117. Boelens JJ. Trends in haematopoietic cell transplantation for inborn errors of metabolism. J Inherit Metab Dis. 2006;29:413–420
  118. Cox-Brinkman J, Boelens JJ, Wraith JE, O'Meara A, Veys P, Wijburg FA, et al. Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. Bone Marrow Transplant. 2006;38:17–21
  119. Tolar J, Grewal SS, Bjoraker KJ, et al. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome. Bone Marrow Transplant. 2007;41:531–535
  120. Kakkis ED. Enzyme replacement therapy for the mucopolysaccharide storage disorders. Expert Opin Investig Drugs. 2002;11:675–685
  121. Wraith JE. Enzyme replacement therapy in mucopolysacccharidosis type I: progress and emerging difficulties. J Inherit Metab Dis. 2001;24:245–250
  122. United States Food and Drug Administration. Aldurazyme approval information. Available at http://www.fda.gov/cder/biologics/products/larobio043003.htm2003;
  123. European Agency for the Evaluation of Medical Products. Aldurazyme approval information. Available at http://www.emea.eu.int/humandocs/Humans/EPAR/aldurazyme/aldurazyme.htm2003;
  124. Giugliani R, Muñoz Rojas V, Martins AM, Valadares ER, Clarke JTR, Góes J, et al. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Mol Genet Metab. 2008;In press
  125. Clarke L, Wraith JE, Beck M, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;In press
  126. Pastores GM, Wraith JE, Clarke LA, et al. The clinical benefit of Aldurazyme (laronidase) for the treatment of MPS I. Am J Hum Genet. 2003;73:624
  127. Bajbouj M, Beck M, Wraith JE, et al. Efficacy of Aldurazyme enzyme replacement therapy on joint mobility I MPS I. Am J Hum Genet. 2003;73:621
  128. Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004;144:561–562
  129. Miebach E. Enzyme replacement therapy in mucopolysaccharidosis type I. Acta Paediatr Suppl. 2005;94:58–60
  130. Wraith JE. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother. 2005;6:489–506
  131. Wraith JE, Hopwood JJ, Fuller M, Meikle PJ, Brooks DA. Laronidase treatment of mucopolysaccharidosis I. BioDrugs. 2005;19:1–7
  132. Braunlin EA, Berry JM, Whitley CB. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am J Cardiol. 2006;98:416–418
  133. Soutar RL, Mercer J, Wraith JE. Impact of 144 weeks of laronidase therapy on body functions, endurance and general well-being in a Hurler-Scheie patient. J Inherit Metab Dis. 2006;29:590
  134. Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2007;90:171–180
  135. Sardón O, García Pardos C, Mintegui J, Pérez Ruiz E, Coll MJ, Chabás A, et al. Outcome of two patients with Hurler's syndrome under enzyme replacement therapy with human recombinant alpha-L-iduronidase. Ann Pediatr (Barc). 2005;63:61–67
  136. Tokic V, Barisic I, Huzjak N, Petkovic G, Fumic K, Paschke E. Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I. Eur J Pediatr. 2007;166:727–732
  137. Anbu AT, Mercer J, Wraith JE. Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I. J Inherit Metab Dis. 2006;29:230–231
  138. Wegrzyn G, Tylki-Szymańska A, Liberek A, Piotrowska E, Jakóbkiewicz-Banecka J, Marucha J, et al. Rapid deterioration of a patient with mucopolysaccharidosis type I during interruption of enzyme replacement therapy. Am J Med Genet A. 2007;143:1925–1927
  139. Anson DS, Bielicki J, Hopwood JJ. Correction of mucopolysaccharidosis type I fibroblasts by retroviral-mediated transfer of the human alpha-L-iduronidase gene. Hum Gene Ther. 1992;3:371–379
  140. Hartung SD, Frandsen JL, Pan D, Koniar BL, Graupman P, Gunther R, et al. Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol Ther. 2004;9:866–875
  141. Lutzko C, Kruth S, Abrams-Ogg AC, Lau K, Li L, Clark BR, et al. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency. Blood. 1999;93:1895–1905
  142. Shull RM, Lu X, McEntee MF, Bright RM, Pepper KA, Kohn DB. Myoblast gene therapy in canine mucopolysaccharidosis. I: abrogation by an immune response to alpha-L-iduronidase. Hum Gene Ther. 1996;7:1595–1603

 Please see the Author Disclosures section at the end of this article.

PII: S0022-3476(09)00675-1

doi: 10.1016/j.jpeds.2009.07.005

The Journal of Pediatrics
Volume 155, Issue 4, Supplement , Pages S32-S46 , October 2009

Article Tools